新股消息 | 益方生物(688382.SH)递表港交所

Group 1 - The core viewpoint of the news is that Yifang Biotechnology (Shanghai) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - Yifang Biotechnology is a research-driven biopharmaceutical company based in China, focusing on significant diseases with unmet needs, including oncology, autoimmune diseases, and metabolic diseases [1] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, which includes two commercialized products (BPI-D0316 and D 1553), two core products in clinical stages (D-2570 and D-0502), one clinical candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [1]